Stockscreener 앱 받기
41.68
2.01%
0.82
Royalty Pharma Plc 주식(RPRX)의 최신 뉴스
Royalty Pharma stock hits 52-week high at $41.71 By Investing.com - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $41.71 - Investing.com
Royalty Pharma Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38 - marketscreener.com
Ruffer LLP Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Mitsubishi UFJ Trust & Banking Corp Sells 198,889 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cullen Frost Bankers Inc. Raises Position in Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma's (RPRX) Dividend Hike and Guidance Reset Change Its Efficiency and Growth Narrative - Sahm
(RPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer on Royalty Pharma: "It's a Terrific Company" - Finviz
84,741 Shares in Royalty Pharma PLC $RPRX Bought by Oxbow Advisors LLC - MarketBeat
Jim Cramer on Royalty Pharma: “It’s a Terrific Company” - Insider Monkey
Jim Cramer Shared His Takes on These 16 Stocks - Insider Monkey
Baillie Gifford & Co. Trims Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.7 million - Investing.com
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Smart Money: Is UAMY stock a buy or sellGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's - simplywall.st
How Investors May Respond To Royalty Pharma (RPRX) Dividend Hike Amid Insider Sales And Results Countdown - Yahoo Finance
Royalty Pharma (RPRX) Valuation Check After Recent Share Pullback And Strong 1 Year Return - Yahoo Finance
Patient Capital Management LLC Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Dividend Hike Highlights Income Appeal And Undervaluation - Sahm
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $790,400.00 in Stock - MarketBeat
Royalty Pharma to announce fourth quarter and full year 2025 financial results on February 11, 2026 - marketscreener.com
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - The Globe and Mail
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - Quiver Quantitative
Sumitomo Mitsui Trust Group Inc. Buys 207,338 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Nordea Investment Management AB Acquires 120,004 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Latham Watkins Advises on Royalty Financing Agreement Between Teva and Royalty Pharma - Latham & Watkins LLP
Royalty Pharma announces planned legal leadership transition - MSN
Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Aug Technicals: Will Royalty Pharma plc stock remain a Wall Street favoriteDollar Strength & High Win Rate Trade Alerts - moha.gov.vn
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Urist Marshall, evp at Royalty Pharma, sells $815k in shares By Investing.com - Investing.com Canada
Urist Marshall, evp at Royalty Pharma, sells $815k in shares - Investing.com Australia
Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing - marketscreener.com
Liquidity Mapping Around (RPRX) Price Events - Stock Traders Daily
Will Royalty Pharma plc stock remain a Wall Street favoriteNew Guidance & Safe Entry Trade Signal Reports - Bộ Nội Vụ
Royalty pharma reports record year for royalty funding market By Investing.com - Investing.com Nigeria
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment - MSN
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug - StreetInsider
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
1.27%
자본화:
|
볼륨(24시간):